Zhao Jiaqi, Du WenLi, Tao XiaoLiang, Li AiAi, Li Yi, Zhang Shuai
Orthopedics Department, The First Affiliated Hospital of Army Medical University, Chongqing, China.
Emergency Department, Affiliated Hospital of Southwest Medical University, Sichuan Province, Luzhou City, China.
Sci Rep. 2025 Jan 13;15(1):1790. doi: 10.1038/s41598-025-85937-9.
The aim of this study is to elucidate the disparities in survival and risk factors among different subtypes of liposarcoma, through analysis of epidemiological and prognostic data. The study cohort consisted of 12,822 patients diagnosed with liposarcoma in the United States between 2000 and 2021, whose data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program. The prognosis for different subtypes of liposarcoma and the associated factors such as age, tumor stage, intervention, gender, tumor grade, location, size, chemotherapy and radiotherapy, were retrieved from the database. Well-differentiated liposarcoma demonstrated the most favorable prognosis, with 5-year and 10-year survival rates of 82% and 68%, respectively, followed by myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma, which exhibited the poorest prognosis. Advanced age, higher tumor stage, and the absence of surgical intervention were associated with inferior survival outcomes across all subtypes. Male gender, higher pathological grade, and primary tumor sites outside the extremities were identified as risk factors for the prognosis of subtypes other than pleomorphic liposarcoma. Larger tumor size was an indicator of a worse prognosis in subtypes other than well-differentiated liposarcoma. Chemotherapy was a risk factor for the prognosis of well-differentiated and myxoid liposarcomas but had no significant correlation with the prognosis of pleomorphic and dedifferentiated liposarcomas. Radiotherapy served as a protective factor for the prognosis of subtypes other than well-differentiated liposarcoma. Survival and prognostic factors vary among the major subtypes of liposarcoma, necessitating individualized analysis for each subtype. Poorer outcomes can be anticipated in the dedifferentiated and pleomorphic subtypes, while well-differentiated and myxoid liposarcomas exhibit relatively favorable prognoses.
本研究旨在通过分析流行病学和预后数据，阐明不同亚型脂肪肉瘤在生存情况和危险因素方面的差异。研究队列包括2000年至2021年在美国被诊断为脂肪肉瘤的12822例患者，其数据来自监测、流行病学和最终结果（SEER）计划。从数据库中获取了不同亚型脂肪肉瘤的预后情况以及年龄、肿瘤分期、干预措施、性别、肿瘤分级、位置、大小、化疗和放疗等相关因素。高分化脂肪肉瘤预后最为良好，5年和10年生存率分别为82%和68%，其次是黏液样脂肪肉瘤、多形性脂肪肉瘤和去分化脂肪肉瘤，其预后最差。高龄、较高的肿瘤分期以及未进行手术干预与所有亚型的较差生存结果相关。男性、较高的病理分级以及四肢以外的原发肿瘤部位被确定为除多形性脂肪肉瘤外其他亚型预后的危险因素。较大的肿瘤大小是除高分化脂肪肉瘤外其他亚型预后较差的一个指标。化疗是高分化和黏液样脂肪肉瘤预后的危险因素，但与多形性和去分化脂肪肉瘤的预后无显著相关性。放疗是除高分化脂肪肉瘤外其他亚型预后的保护因素。脂肪肉瘤主要亚型的生存和预后因素各不相同，需要对每个亚型进行个体化分析。去分化和多形性亚型的预后可能较差，而高分化和黏液样脂肪肉瘤的预后相对良好。
